Chengdu Better New Life Biotechnology

Chengdu Better New Life Biotechnology is a specialized subsidiary of Chengdu Better Pharmaceutical focused on the research and development of advanced cell and gene therapies. The company primarily develops Chimeric Antigen Receptor T-cell (CAR-T) and T-Cell Receptor (TCR-T) therapies aimed at treating refractory solid tumors. Its lead program is a CAR-T therapy targeting Claudin 18.2, which has entered clinical trials in China for indications such as gastric and pancreatic cancer. By utilizing the extensive manufacturing and commercialization infrastructure of its parent company, Better New Life aims to provide accessible next-generation immunotherapies. The firm operates out of Chengdu's high-tech medical zones, maintaining state-of-the-art R&D and GMP-compliant facilities. It represents the strategic expansion of the Better Pharmaceutical group into the innovative biologics and precision medicine space.